Free shipping on all orders over $ 500

Lambrolizumab

Cat. No. M6220
Lambrolizumab Structure
Synonym:

MK-3475, Pembrolizumab

Size Price Availability Quantity
5mg USD 1235 In stock
10mg USD 2000 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Lambrolizumabis a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

In addition to Melanoma and Lung carcinoma, Lambrolizumab has also demonstrated efficacy in other advanced solid tumors and hematologic malignancies. Lambrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight
Formula
CAS Number
Purity >99%
Solubility
Storage at -20°C
References

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E, et al. Expert Rev Anticancer Ther. 2015;15(9):981-93. PMID: 26313415.

Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS, et al. Ann Pharmacother. 2015 Aug;49(8):907-37. PMID: 25991832.

Related PD-1/PD-L1 Products
Pembrolizumab

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

Atezolizumab

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

Nivolumab

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Lambrolizumab, MK-3475, Pembrolizumab supplier, PD-1/PD-L1, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.